torbjorntrainer1738.blogspot.com
Lead Therapeutics is developing drugs for cancer andinfectioue diseases. According to the SEC filing, the San Calif., company has raised $3 million so far in the Other investors include ProQuesg Investmentsof Princeton, N.J., and Mustang Ventures, a ventur capital firm based in Shanghai, China. Pappas Ventures participatedx in Lead’s Series A round, which raised $17 milliohn in November 2007. With that round, Pappas Managing Partner Arthur Pappasjoined Lead’s board of directors. Lead’s cancer drug would work in conjunction with chemotherapy andradiationj treatment, which both work by damaging the DNA of cancert cells.
The drug targets a proteinb that cancer cells can use to repair thedamaged DNA. The company expects to select a lead compoundin mid-2009 and begin clinicalo trials by mid-2010.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment